Table III.
Incidence rates of outcomes by follow-up period and treatment group
| Condition | Group | Incidence per 1000 child days | Incidence rate ratio (95% CI) | P value for overall differences among the 3 study groups |
|---|---|---|---|---|
| Influenza season | ||||
| Febrile RTI | TIV+PCV7 | 5.2 (4.2 to 6.5) | 0.76 (0.58 to 0.99) | .13 |
| TIV+plac | 6.0 (5.0 to 7.2) | 0.87 (0.68 to 1.12) | ||
| HBV+plac | 6.9 (5.9 to 8.2) | |||
| GP visit | TIV+PCV7 | 2.2 (1.6 to 3.0) | 0.75 (0.50 to 1.12) | .15 |
| TIV+plac | 2.0 (1.4 to 2.7) | 0.67 (0.45 to 1.02) | ||
| HBV+plac | 2.9 (2.3 to 3.7) | |||
| Antibiotic prescription | TIV+PCV7 | 1.0 (0.6 to 1.6) | 0.73 (0.40 to 1.32) | .57 |
| TIV+plac | 1.2 (0.8 to 1.9) | 0.89 (0.50 to 1.61) | ||
| HBV+plac | 1.4 (0.9 to 2.1) | |||
| AOM | TIV+PCV7 | 0.5 (0.3 to 1.0) | 0.43 (0.20 to 0.94) | .01 |
| TIV+plac | 0.4 (0.2 to 0.8) | 0.29 (0.12 to 0.70) | ||
| HBV+plac | 1.2 (0.8 to 1.9) | |||
| Outside influenza season | ||||
| Febrile RTI | TIV+PCV7 | 4.0 (3.4 to 4.7) | 1.20 (0.95 to 1.52) | .29 |
| TIV+plac | 3.5 (2.9 to 4.2) | 1.05 (0.82 to 1.34) | ||
| HBV+plac | 3.3 (2.8 to 3.9) | |||
| GP visit | TIV+PCV7 | 1.2 (0.9 to 1.6) | 0.82 (0.56 to 1.21) | .54 |
| TIV+plac | 1.2 (0.9 to 1.7) | 0.82 (0.55 to 1.23) | ||
| HBV+plac | 1.5 (1.1 to 1.9) | |||
| Antibiotic prescription | TIV+PCV7 | 0.7 (0.5 to 1.1) | 0.89 (0.54 to 1.44) | .33 |
| TIV+plac | 0.6 (0.4 to 0.9) | 0.67 (0.39 to 1.16) | ||
| HBV+plac | 0.8 (0.6 to 1.2) | |||
| AOM | TIV+PCV7 | 0.5 (0.3 to 0.7) | 2.00 (1.02 to 3.93) | .13 |
| TIV+plac | 0.3 (0.2 to 0.6) | 1.41 (0.65 to 3.03) | ||
| HBV+plac | 0.2 (0.1 to 0.4) | |||